Based on the above research, in August 2018, the FDA approved pembrolizumab in combination with pemetrexed and platinum as first-line treatment of patients with metastatic NS-NSCLC and without EGFR or ALK genomic tumor aberrations. The gene discussed is ALK; the disease is non-small cell lung carcinoma.